New hope for Tough-to-Treat blood cancer: experimental drug enters human testing
NCT ID NCT07490613
Summary
This is the first study in people testing a new drug called SHR-3836 for multiple myeloma, a type of blood cancer. It aims to find a safe dose and see how the body handles the drug in 99 adults whose cancer has come back or stopped responding to standard treatments. The main goals are to check for side effects and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Contact
Conditions
Explore the condition pages connected to this study.